The Centre has brought 42 non-scheduled anti-cancer drugs under the price control, capping trade margin at 30 per cent, which will reduce their retail prices by up to 85 per cent. The National Pharmaceutical Pricing Authority (NPPA) yesterday invoked extraordinary powers in public interest, under Para 19 of the Drugs (Prices Control) Order, 2013 to bring 42 non-scheduled anti-cancer drugs under price control through trade margin rationalisation.<br />”<br />”An official release said as per data available with NPPA, the margin on the selling price (MRP) for 105 brands will be reduced up to 85 per cent entailing minimum. Currently, 57 anti-cancer drugs are under price control as&nbsp; scheduled formulations.<br />”<br />”<span style="color: #222222;">The revised prices will come into effect from 8 of next month.</span><br />